Literature DB >> 667500

The binding of haloperidol to human blood platelets and interactions with 5-hydroxytryptamine and dopamine.

D J Boullin, D Molyneux, B Roach.   

Abstract

1 The binding of [3H]-5-hydroxytryptamine ([3H]-5-HT), [3H]-haloperidol and [3H]-dopamine to human blood platelets was investigated and the effects of unlabelled haloperidol on [3H]-5-HT binding and (+)- and (-)-butaclamol on [3H]-haloperidol were studied. 2 Scatchard analysis did not show any specific binding of [3H]-haloperidol or [3H]-dopamine to platelets, but two binding sites were identified for binding of [3H]-5-HT. 3 Unlabelled haloperidol reduced the binding of 5-HT in concentrations comparable to those inhibigint 5-HT-induced platelet aggregation; (+)- and (-)-butaclamol did not affect the binding of [3H]-haloperidol. 4 It is concluded that haloperidol binding represents saturation of the platelet membrane, and that the platelet is not a suitable model for investigation of dopamine-drug interactions.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667500      PMCID: PMC1668091          DOI: 10.1111/j.1476-5381.1978.tb07812.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Proceedings: Human blood platelet aggregation induced by dopamine, 5-hydroxyptrypamine and analogues.

Authors:  D J Boullin; A R Green; R P Grimes
Journal:  J Physiol       Date:  1975-11       Impact factor: 5.182

2.  Proceedings: Inhibition of 5-hydroxy-(3H)-tryptamine binding to rat blood platelets by 5-HT antagonists and uptake inhibitors.

Authors:  A H Drummond; J L Gordon
Journal:  Br J Pharmacol       Date:  1975-10       Impact factor: 8.739

3.  Dopamine receptor binding in the corpus striatum of mammalian brain.

Authors:  D R Burt; S J Enna; I Creese; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

4.  Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.

Authors:  D J Boullin; P A Glenton
Journal:  Br J Pharmacol       Date:  1978-04       Impact factor: 8.739

5.  Binding of 5-hydroxytryptamine to human blood platelets [proceedings].

Authors:  D J Boullin; P A Glenton; D Molyneux; J R Peters; B Roach
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

6.  Specific binding sites for 5-hydroxytryptamine on rat blood platelets.

Authors:  A H Drummond; J L Gordon
Journal:  Biochem J       Date:  1975-07       Impact factor: 3.857

7.  The accumulation of guanethidine by human blood platelets.

Authors:  D J Boullin; R A O'Brien
Journal:  Br J Pharmacol       Date:  1969-01       Impact factor: 8.739

8.  Brain receptors for antipsychotic drugs and dopamine: direct binding assays.

Authors:  P Seeman; M Chau-Wong; J Tedesco; K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

9.  Mechanisms by which human blood platelets accumulate glycine, gaba and amino acid precursors of putative neurotransmitters.

Authors:  D J Boullin; A R Green
Journal:  Br J Pharmacol       Date:  1972-05       Impact factor: 8.739

  9 in total
  3 in total

1.  Long-term low dose haloperidol treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR, and clinical response.

Authors:  M G Grimaldi
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

2.  Ect and platelet 5ht uptake in major depression.

Authors:  P K Dalal; N Lal; J K Trivedi; P K Seth; A K Agarwal; A Khalid
Journal:  Indian J Psychiatry       Date:  1997-10       Impact factor: 1.759

3.  The binding characteristics of [3H]-dihydroergocryptine on intact human platelets.

Authors:  J M Elliott; D G Grahame-Smith
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.